Effect of the combination therapy of liraglutide, a GLP-1 receptor analog, and IDegAsp in patients with type 2 diabetes
Not Applicable
- Conditions
- Type2 diabetes
- Registration Number
- JPRN-UMIN000033511
- Lead Sponsor
- Yokohama City University Medical Center Department of Endocrinology and Diabetes
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients with severe renal dysfunction including patients requiring hemodialysis or peritoneal dialysis(eGFR<30ml/min). 2)pregnant 3)Patients who have severe diabetic ketosis, diabetic coma. 4)Patients with severe infection, severe injury or perioperative state.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The change in QOL scores from baseline to 3 months in patients with switched therapy to Liraglutide/IDegAsp.
- Secondary Outcome Measures
Name Time Method Difference of change in HbA1c, body weight, units of insulin dose, frequency of hypoglycemia (SMBG), SD and CV % of FPG on SMBG, clinical and laboratory parameters
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the synergistic effects of liraglutide and IDegAsp in type 2 diabetes management?
How does the combination of liraglutide and IDegAsp compare to standard-of-care therapies in glycemic control and weight management for type 2 diabetes patients?
Which biomarkers are associated with improved outcomes in type 2 diabetes patients receiving liraglutide and IDegAsp combination therapy?
What are the potential adverse events and management strategies for patients on liraglutide and IDegAsp combination therapy in type 2 diabetes?
Are there alternative GLP-1 receptor analog and insulin combination approaches that show competitive efficacy to liraglutide and IDegAsp in type 2 diabetes treatment?